Abacavir
- Generic Name
- Abacavir
- Brand Names
- Epzicom, Kivexa, Triumeq, Trizivir, Ziagen
- Drug Type
- Small Molecule
- Chemical Formula
- C14H18N6O
- CAS Number
- 136470-78-5
- Unique Ingredient Identifier
- WR2TIP26VS
- Background
Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
- Indication
Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection. It is available in a combination product alongside dolutegravir and lamivudine for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 80
- Registration Number
- NCT00002213
- Locations
- 🇺🇸
Niaid / Nih, Bethesda, Maryland, United States
🇺🇸Northwestern Univ Med School AIDS Treatment Unit, Chicago, Illinois, United States
🇺🇸Univ Int Med Assoc Inc / Holmes Hosp / U of Cincinnati, Cincinnati, Ohio, United States
A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 230
- Registration Number
- NCT00005106
- Locations
- 🇺🇸
Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸THE Clinic, Los Angeles, California, United States
🇺🇸Maxine Liggins, Los Angeles, California, United States
Safety and Effectiveness of a Combination Anti-HIV Drug Treatment
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 150
- Registration Number
- NCT00005018
- Locations
- 🇺🇸
East Bay AIDS Ctr, Berkeley, California, United States
🇺🇸Altamed Medical Health Services, Los Angeles, California, United States
🇺🇸Gary Richmond MD, Fort Lauderdale, Florida, United States
A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002390
- Locations
- 🇩🇪
Universitatsklinikurn Frankfurt, Frankfurt, Germany
🇫🇷Group Hospier Pitie-Salpetriere / Maladies Infec et Trop, Paris Cedex 13, France
🇩🇪Universitat Erlangen, Erlangen, Germany
A Study of 1592U89 in HIV-Infected Adults
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002200
- Locations
- 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States
The Effect of Teaching HIV-Infected Patients About HIV and Treatment
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 200
- Registration Number
- NCT00002409
- Locations
- 🇺🇸
Specialty Med Care Ctrs of South Florida Inc, Miami, Florida, United States
🇺🇸Rush Med College / Dept of Infectious Diseases, Chicago, Illinois, United States
🇺🇸Santa Rosa Med Ctr / Baptist Med Ctr, San Antonio, Texas, United States
A Study of 1592U89 in HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 48
- Registration Number
- NCT00002388
- Locations
- 🇺🇸
Albany Med College / Albany Med Ctr Hosp, Albany, New York, United States
🇺🇸Evanston Hosp / Clinical Pharmacology Unit, Evanston, Illinois, United States
🇺🇸Fenway Community Health Ctr / Research Dept, Boston, Massachusetts, United States
A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 60
- Registration Number
- NCT00002183
- Locations
- 🇺🇸
UCSD, San Diego, California, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
A Study of 1592U89 in HIV-Infected Children
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 250
- Registration Number
- NCT00002197
- Locations
- 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States
Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 624
- Registration Number
- NCT00009061
- Locations
- 🇺🇸
North Jersey Community Research Initiative, Newark, New Jersey, United States
🇺🇸Nicholas Bellos, Dallas, Texas, United States
🇺🇸Therafirst Med Ctr, Fort Lauderdale, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.